PAOLI, Pa., Feb. 8, 2016 /PRNewswire/ -- As part of a major growth and expansion initiative, Dune Medical Devices Ltd has announced today the appointment of Lori Chmura as President of Dune Inc., its U.S. division. With more than 20 years in the industry, Chmura's extensive experience in the medical device space will play a large role in the advancement of Dune Medical Devices.

In her new role, Lori will be responsible for leading all sales, marketing and operational functions in the U.S. She is tasked with building a strong team while growing the overall business and meeting the commercial milestones. She will also be accountable for building a solid foundation from which Dune can expand beyond the US and beyond breast cancer.

"Lori's experience and talents will be an asset to the development of our U.S. presence," said Dan Hashimshony, chief executive officer, Dune Medical Devices Ltd. "We are growing rapidly and we hope to continue­—and amplify—this positive trajectory. Lori is a strong leader and we feel she is the ideal person for this role. I look forward to seeing what she brings to the company."

Last month, it was announced that 100 breast centers have selected MarginProbe to help improve surgical outcomes for lumpectomy patients, marking a significant corporate milestone for the emerging medical device company. To date, there have been over 7,000 MarginProbe lumpectomies performed in 27 states nationwide and in Israel.

Since bringing on a direct sales team in the U.S. in late 2013, the company has achieved double-digit growth quarter over quarter for eight consecutive quarters, with no signs of slowing down. In 2015, the company's average quarter-to-quarter growth rate for installed systems reached 25 percent.

"I am thrilled to be a part of the Dune Medical team," said Lori Chmura, President, Dune Medical Inc. "Answering the question, 'did we get it all?' after cancer surgery is one of the most terrifying aspects of the cancer diagnosis. We have the opportunity to improve cancer treatment through the introduction of margin detection. Expanding access to MarginProbe for the many thousands of breast cancer patients will ensure that they will receive the best chance of avoiding the risk of a second surgery, as well as a possible recurrence. It is exciting and revolutionary to be working with a company that is developing the market and becoming the standard of care for margin detection for breast cancer today and for prostate, colon and lung cancers in the future. I am very honored to be able to participate in this journey and enthusiastic about leveraging my expertise to help with the development of the US organization."

More People on the Move